MUNDIPHARMA
Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/
The product is an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3
It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1
Work is already under way to source an alternative to the HFA-227 gas used in fluticasone propionate/formoterol fumarate pMDI. This new collaboration will revitalise the efforts to identify and switch to a more environmentally friendly propellant. If successful, this will result in a significantly lower impact on global warming and alignment with European Union regulation on fluorinated greenhouse gases.1
With more than 262 million people living with asthma globally, the reformulation of some asthma treatments to reduce carbon emissions could have a significant impact on the global carbon footprint.4,5
“We are dedicated to positively influencing the life of asthma patients across the globe. This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler. We are determined to achieve this before the European Union ban of HFA (hydrofluoroalkane) gases comes into effect, and our collaboration with Vectura demonstrates this, as well as our aim to an overall commitment to sustainable healthcare innovation,” said Yuri Martina, Chief Development and Medical Officer at Mundipharma.
“At Vectura, our priority is to ensure that patients prescribed fluticasone propionate/formoterol fumarate pMDI can continue to have access to this treatment. Using Vectura’s expertise and extensive track record in the development of inhaled prescription medicines and devices, we believe the collaboration with Mundipharma will enable us to meet our environmental responsibilities and enable patients to use fluticasone propionate/formoterol fumarate pMDI in the years to come,” said Geraldine Venthoye, Chief Scientific Officer, Vectura.
®: FLUTIFORM is a registered trademark of Jagotec AG used under licence by Mundipharma.
References
- Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases and repealing Regulation (EC) No 842/2006 Text with EEA relevance. Available at: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=uriserv:OJ.L_.2014.150.01.0195.01.ENG (last accessed March 2024)
- flutiform® pMDI emissions manufacturing data, Q4 2022 – Q4 2023. Data on file.
- flutiform® Summary of Product Characteristics (SmPC). Last updated 13 April 2022. https://www.emcpi.com/pi/26954. (last accessed April 2024).
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22
- NHS England, World Asthma Day: tackling climate change and improving respiratory care. Available at https://www.england.nhs.uk/blog/world-asthma-day-tackling-climate-change-and-improving-respiratory-care/ (last accessed March 2024)
*ENDS*
Job code: SciA-FLU-2400001| Date of preparation: April 2024
|
Notes to Editors
About flutiform® (fluticasone propionate/formoterol fumarate):
flutiform® is an inhaler (a pressurised metered-dose inhalation, suspension) which contains two active ingredients, fluticasone propionate and formoterol fumarate dihydrate.3 This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform®) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β₂ agonist) is appropriate for the management of asthma symptoms.3
About Mundipharma:
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of respiratory, pain management, infectious disease as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
About Vectura:
Vectura is a specialist inhalation contract development and manufacturing organization (CDMO) that provides inhaled drug development solutions to help customers bring their medicines to patients. With 25 years’ experience, it provides a combination of formulation science, device technology, and inhaled development expertise. Vectura is a member of the Vectura Fertin Pharma group of companies. For more information visit www.vectura.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416962162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PPG introduces PPG MIX‘N’SHAKE automated stirring technology for body shops14.10.2025 08:30:00 CEST | Press release
System improves productivity, reduces waste, enhances color accuracy PPG (NYSE: PPG) today announced the introduction of PPG MIX‘N’SHAKE™ automated stirring technology designed to eliminate traditional manual stirring methods in the automotive refinish industry. The system, which is available globally, improves paint mix consistency, reduces consumable waste and saves time for painters and body shops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013065453/en/ PPG MIX’N’SHAKE™ automated stirring technology replaces manual stirring processes to ensure a homogenized paint mix, complete color accuracy, and a better workplace. The PPG Mix‘n’Shake system will debut at the EQUIP AUTO trade show in Paris taking place Oct. 14-18. PPG will also showcase its PPG LINQ™ digital ecosystem, which is a finalist for the prestigious EQUIP AUTO Innovation Award. Because the PPG Mix‘n’Shake system eliminates manual stirring, it ensures con
Glesys to Acquire Verne’s Managed Private Cloud Operations and Two Data Centers in Finland14.10.2025 08:00:00 CEST | Press release
Verne, the leading provider of low-carbon high-performance data centers across the Nordics, has today announced that Glesys, a leading Nordic provider of cloud and IaaS services, will acquire Verne’s managed private cloud operations in Finland, including data center facilities in Pori and Tampere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006898290/en/ Pori Data Center Tunnel Corridor The agreement reflects both companies’ strategic priorities: for Glesys, it represents an important step in expanding its cloud and IaaS services, strengthening its position as a market leader in the Nordics and enhancing its capacity to deliver secure, energy-efficient and scalable solutions in the region. For Verne, it supports a sharpened focus on delivering low-carbon, high-performance colocation for AI and enterprise workloads, including its expansion plans in Mäntsälä, announced earlier this year. Glesys and Verne will continue to
Avanzanite Expands Italian Operations with General Manager Appointment14.10.2025 07:30:00 CEST | Press release
Giovanni Galliano joins Avanzanite having led 12 orphan medicine launches in Italy and overseen operations with more than €100 million in annual revenue. Avanzanite initiates engagement with the Italian rare blood disorder community who include the largest number of thalassemia patients in Europe. Avanzanite’s Q3 2025 revenues are 20% higher than Q2 2025, marking the strongest quarter to date. Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, announced today the appointment of Giovanni Galliano as General Manager for Italy. As the seventh executive leadership hire in 2025, this appointment further strengthens Avanzanite’s “Champions League” team of now more than 60 pharma professionals, while expanding operations into the European Union's third-largest economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013986565/en/ Giovanni Galliano, th
The Estée Lauder Companies Opens Global Fragrance Atelier in Paris, Accelerating Next-Generation Innovation in Perfume Artistry14.10.2025 07:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL), under the High Patronage of Mr. Emmanuel Macron, President of the French Republic,today announced the opening of its Fragrance Atelier within its new La Maison des Parfums on Rue Volney in Paris. This newly established global innovation hub is fully dedicated to world-class fragrance expertise, advanced technologies and cutting-edge capabilities, and will accelerate the company’s strategic ambitions in luxury and prestige fragrances. Rooted in the legacy of Mrs. Estée Lauder’s pioneering vision and her lifelong passion for fragrance, the Atelier’s opening marks a significant milestone in the company’s longstanding commitment to fragrance excellence and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013447078/en/ The Exterior of La Maison des Parfums “It is with great pride and excitement that we open our Fragrance Atelier in Paris,” said Stéphane de La Faverie, Pre
Ant International’s WorldFirst Launches in Thailand to Offer Unified Global Account Service for Thai SMEs14.10.2025 06:43:00 CEST | Press release
WorldFirst has officially launched in Thailand through the partnership with 2C2P, offering Thai SMEs the innovative unified global account service to simplify international transactions and fuel expansion.The Thai launch expands WorldFirst’s investment in Asia Pacific where its services are available to support businesses in China, Hong Kong SAR, Australia, New Zealand and Singapore. Ant International’s WorldFirst, an all-in-one digital cross-border payment and treasury account service for global businesses, announced the official launch in Thailand at its Bangkok Global Voyage event. It will provide Thai SMEs with efficient and secure global account service to simplify international payments and fuel their expansion. The offerings are delivered through the partnership with 2C2P and its subsidiary 2C2P Plus, a Southeast Asia-based payments provider licensed by the Bank of Thailand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom